Recent News
Powered by Alpha Vantage
No recent news found.
AI Tools
Key Metrics
Trend: Downtrend
Source: Snapshot
SAB Biotherapeutics, Inc., a biopharmaceutical company, develops immunotherapies against infectious diseases, autoimmune diseases, and oncology. The company is headquartered in Sioux Falls, South Dakota with an additional office in Cambridge, Massachusetts.
52W High
$0.15
52W Low
$0.02
MA Status:
50D: Below
200D: Below
Beta (~1 neutral, <0.9 lower risk)
0.55
Valuation
Attractive
As of 2025-06-30 (Overview)
Trailing P/E (<15 better)
0.09
Forward P/E (<15 better)
N/A
EV/EBITDA (<8 favorable)
N/A
EV/Revenue (<3 favorable)
N/A
P/S (TTM) (<3 favorable)
N/A
P/B (<3 favorable)
N/A
Ownership
Source: Overview
Insiders (1–5% typical)
0.00%
Institutions (25–75% balanced)
0.00%
Shares Outstanding
0
Float
7,555,400
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2025-06-30 (Overview)
Revenue (TTM)
114,700
Gross Profit (TTM)
-30,021,696
EPS (TTM)
0.29
Profit Margin (>10% good)
N/A
Operating Margin (TTM) (higher better)
-364.63%
ROE (TTM) (>15% strong)
-1.28%
EPS YoY (Quarterly) (>10% good)
N/A
Revenue YoY (Quarterly) (>8% good)
-0.62
Momentum
Bearish momentumValue
-0.0004
Previous
-0.0005
Trend
Rising
Signal Cross
No cross
As of
Sep. 12, 2025